News | February 15, 2025
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Branded formulation business continues to perform well across domestic and export markets
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Subscribe To Our Newsletter & Stay Updated
